Home › Companies › ACTU

Actuate Therapeutics

Market cap $15.2M 60.4M shares (10-Q, Nov 13, 2026) × $0.252 close Nov 17, 2026

Most recent annual filing: 2026-01-15

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. Elraglusib Ph3 start2H 2026Elraglusib Ph3 start, 2H 2026, routine
  2. Elraglusib Oral Tablet Ph1 start2H 2026Elraglusib Oral Tablet Ph1 start, 2H 2026, routine
  3. corporate listing updateJan 11, 2027corporate listing update, Jan 11, 2027, routine
  4. Nasdaq listing - MVLS testJan 11, 2027Nasdaq listing - MVLS test, Jan 11, 2027, routine
  5. Nasdaq listing - bid priceApr 26, 2027Nasdaq listing - bid price, Apr 26, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Capital (as filed)

Cash
$2.1M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$3.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$13.9M cash per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (18)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (18 calls)

Every verdict Biotech Distilled has published on Actuate Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Avoid Actuate Therapeutics (ACTU): Scientific Deep Dive for Elraglusib Financing overhang from $100M ATM, commercially inferior efficacy vs NALIRIFOX, and a potentially false-positive Phase 2 driven by a weak control arm make this uninvestable for new buyers.
  2. Hold UPDATE: Actuate Therapeutics (ACTU) — Finding Green Shoots in the Graveyard Pediatric PRV optionality adds a tangible floor value, but the business remains broken; the scientific probability of success rose while the financing overhang persists.
  3. Avoid UPDATE : Actuate Therapeutics (ACTU) Post-ASCO: The "Tail" Looks Real, but Is the Market is Blind? Strong 24-month survival tail validates the science, but the financing overhang from the ATM is what the market is pricing and new buyers should wait for a secondary offering or partnership announcement.
  4. Avoid Update : Actuate Therapeutics (ACTU) Goes Oral - A Lazarus Patient, A Pill, and An Empty Checkbook The oral melanoma announcement broadens the narrative but does nothing to solve the solvency challenge; the $100M ATM dilution overhang remains the dominant factor.
  5. Avoid UPDATE: Actuate Therapeutics (ACTU) - A Great Science Project Doesn't Pay the Bills Preclinical RAS combination initiative is scientifically sound but does not fund a registrational trial; the dilution gap remains unsolved and the press release is window dressing on a burning building.
  6. Avoid UPDATE: Actuate Therapeutics (ACTU) - The "Going Concern" Ghost and the July 2026 Cliff Annual report formalizes going-concern doubt with a July 2026 cash expiry and $100M ATM locked and loaded; a great molecule trapped inside a broken balance sheet is a recipe for heavy losses.
  7. Hold UPDATE: Actuate Therapeutics (ACTU) - Nature Medicine Blesses the Sledgehammer Nature Medicine peer-reviewed validation materially weakens the weak-control-arm bear case and raises partnership probability, but the July 2026 cash cliff is unchanged so a full buy is not warranted.
  8. Watch UPDATE: Actuate Therapeutics (ACTU) - The Mersana Guy Just Joined the Board Huber's M&A pedigree and the oral IND clearance strengthen the BD/partnership narrative, but the balance sheet is still broken and a dip entry is needed before opening a position.
  9. Watch UPDATE: Actuate Therapeutics (ACTU) - The KRAS Wild-Type Tell KRAS WT subgroup with p<0.001 and FOLFIRINOX-backbone signal sharpen the BD pitch, but with only 8 weeks to the July cash cliff and no partnership announced, the market is pricing in the ATM.
  10. Watch UPDATE: Actuate Therapeutics (ACTU) - Someone Else Is Paying for the Neuroblastoma Trial Cancer Research UK funding the BEACON2 neuroblastoma trial adds capital-efficient PRV optionality, but the pancreatic/financing binary is unchanged with roughly 6 weeks to the July cash cliff.
  11. Avoid UPDATE: Actuate Therapeutics (ACTU) - The Second Clock Just Started Nasdaq MVLS deficiency notice adds a second independent deadline sharing the same cure as the cash cliff, shifting counterparty leverage further toward buyers and worsening the risk-adjusted odds.
  12. Avoid UPDATE: Actuate Therapeutics (ACTU) - $4.4 Million and Six Weeks Q2 10-Q reveals $4.4M cash and a September runway with no partnership signed; the risk profile has moved from binary toward genuinely distressed and waiting for the financing to clear is the better-compensated approach.
  13. Avoid UPDATE: Actuate Therapeutics (ACTU) - The Revolution Medicines Audition Preclinical synergy with two RAS(ON) inhibitors is the sharpest BD pitch the asset has ever had, but it is dish-and-mouse data with no p-values and the equity still faces an imminent financing event that hasn't been priced.
  14. Avoid UPDATE: Actuate Therapeutics (ACTU) - The Dilution Finally Arrives The 50M-share S-1 at ~$0.82 triples the share count and funds survival not a Phase 3; buying ahead of an unpriced float-tripling deal means taking dilution risk without the offering discount.
  15. Avoid UPDATE: Actuate Therapeutics (ACTU) - The Deal Is Chasing the Stock Down Amendment No. 1 upsizes to 65M shares at a lower assumed price that is already 33% above market, net proceeds could come in well under assumption, and the Nasdaq math no longer cures on the new count.
  16. Avoid UPDATE: Actuate Therapeutics (ACTU) - Half the Shares, Half the Cash, Plus Warrants Amendment No. 2 cuts to 40M shares with warrant sweetener raising only ~$18M net — roughly one year of survival — while adding a 25M+ warrant supply ceiling and leaving the Phase 3 unfunded.
  17. Avoid UPDATE: Actuate Therapeutics (ACTU) - Priced at 35.5 Cents Final pricing at $0.355/share raised only ~$11M gross — about two quarters of runway — with a $0.45 warrant ceiling just above the stock and the Phase 3 still unfunded; the terms make the case for staying on the sidelines.
  18. Avoid UPDATE: Actuate Therapeutics (ACTU) - Underwater on Its Own Deal Q3 10-Q shows $2.1M pre-raise cash and negative equity; post-raise going-concern language persists, a reverse split is now formally on management's option list, and the stock trades below the 35.5-cent deal price.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (27)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)